Ligand ID: DXT


Drugbank ID:
DB00254
(Doxycycline)


Indication:
Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

Get human targets for DXT in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'DXT' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU B 425
PHE B 429
ASP B 428
VAL B 433
ILE B 410
1.49A20.00
13.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.74A12.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6m71 NSP8
(SARS-CoV-2)		5 / 9
LEU B 180
ALA B 181
ASP B 163
VAL B 159
ILE B 172
1.61A20.81

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6m71 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ASN A 955
VAL A1008
GLN A1011
LEU A1012
ILE A 770
1.47A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.62A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxs NSP3
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.69A
SO4  B 204 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxs NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.64A
SO4  A 203 (-4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS A 519
THR A 547
LEU B 981
ILE B 980
SER B 974
1.54A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C1055
PRO C 807
THR C 874
GLN C1054
ILE C 818
1.64A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.44A15.90
3.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU C 425
PHE C 429
ASP C 428
VAL C 433
ILE C 410
1.37A15.90
3.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.69A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
LEU B 298
ILE B 323
1.32A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.52A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w37 PROTEIN 7A
(SARS-CoV-2)		5 / 12
HIS A  32
PHE A  31
THR A  13
VAL A  14
LEU A  62
1.56A14.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 9
LEU C 425
PHE C 429
ASP C 428
VAL C 433
ILE C 410
1.47A19.71
13.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w4h NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.30A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w61 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.42A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.69A17.63
14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w6y NSP3
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.67A19.07
12.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w6y NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.71A19.07
12.34
AMP  A 201 ( 4.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.71A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.45A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.31A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.79A16.98
15.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.31A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.73A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wcf NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wen NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wey NSP3
(SARS-CoV-2)		5 / 9
VAL A 359
LEU A 344
ASP A 339
VAL A 369
ILE A 222
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 6
LEU A6909
SER A6896
ASP A6895
HIS B4333
1.72A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.73A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.79A
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU A6909
SER A6896
ASP A6895
HIS B4333
1.79A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.79A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.46A
 NA  A7102 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
LEU B 298
ILE B 323
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER A 274
ASN A  75
PRO A 344
LEU A 298
ILE A 323
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wq3 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL E 155
LEU E 140
ASP E 135
VAL E 165
ILE E  18
1.69A
EDO  E 205 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.68A
EDO  D 208 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL E 155
LEU E 140
ASP E 135
VAL E 165
ILE E  18
1.69A
APR  E 201 ( 4.9A)
None
EDO  B 202 (-4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
APR  A 201 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 126
ALA A 129
ASP A 135
ILE A  18
1.76A
APR  A 201 ( 4.8A)
APR  A 201 (-4.8A)
APR  A 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.69A
APR  C 201 ( 4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.72A
EDO  B 202 (-4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.68A
EDO  C 206 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 6
LEU A 437
SER C   4
PHE A 429
ASP C   5
1.74A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
ASN A 507
PHE A 506
LEU A 673
ILE A 539
SER A 561
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
HIS A 816
HIS A 872
VAL A 435
LEU A 838
ILE A 837
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.75A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ASN A 507
PHE A 506
LEU A 673
ILE A 539
SER A 561
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
NSP7
(SARS-CoV-2)		4 / 6
LEU A 437
SER C   4
PHE A 429
ASP C   5
1.78A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.76A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.50A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.68A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.73A
None